Autopsy report · NCT05164211
Didgeridoo Treatment to Improve Pharyngeal Compliance in Obstructive Sleep Apnea-hypopnea Syndrome in Children
Cause of deathSlow enrollment, also staffing, sites or logistics
“no inclusion since the opening of the centers (difficulties in recruiting staff which impact the functioning of the services)”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Na
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Conditions
- Obstructive Sleep Apnea Syndrome
- Interventions
- Didgeridoo
- Participants
- 0
- Sites
- 1
- Countries
- France
Trials that died the same way
- Efficacy of Transvaginal Repair for Rectocele
“Lack of recruitment in participating centers” - The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients
“Inclusion rate not as expected. Not financially possible to involve other centres.” - Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases
“end of inclusion period and recruitment difficulties” - Knee Nerve Cryoneurolysis and Impact on Pain After Prosthetic Surgery
“the recruitment rate is far too low despite an 18-month extension of the inclusion period” - Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité Tomos Study- Contribution of Tomosynthesis In Locoregional Pretherapeutic Staging of a Breast Tumor: Multicentricity Search
“No more inclusions since august 2013”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.